Smith Jason Drew 4
4 · UroGen Pharma Ltd. · Filed Feb 4, 2025
Insider Transaction Report
Form 4
Smith Jason Drew
General Counsel
Transactions
- Sale
Ordinary Shares
2025-01-31$11.14/sh−3,354$37,364→ 29,781 total - Sale
Ordinary Shares
2025-01-31$11.14/sh−2,767$30,824→ 32,514 total - Exercise/Conversion
Restricted Stock Units
2025-01-31−2,500→ 0 total→ Ordinary Shares (2,500 underlying) - Exercise/Conversion
Restricted Stock Units
2025-01-31−5,500→ 11,000 total→ Ordinary Shares (5,500 underlying) - Exercise/Conversion
Ordinary Shares
2025-01-31+6,667→ 33,135 total - Exercise/Conversion
Restricted Stock Units
2025-01-31−6,667→ 6,667 total→ Ordinary Shares (6,667 underlying) - Sale
Ordinary Shares
2025-01-31$11.14/sh−1,258$14,014→ 26,468 total - Exercise/Conversion
Ordinary Shares
2025-01-31+5,500→ 35,281 total - Award
Restricted Stock Units
2025-01-31+10,000→ 10,000 total→ Ordinary Shares (10,000 underlying) - Exercise/Conversion
Ordinary Shares
2025-01-31+2,500→ 27,726 total
Footnotes (6)
- [F1]Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
- [F2]Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
- [F3]The reporting person was granted RSUs on January 31, 2022 representing 7,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023.
- [F4]The reporting person was granted RSUs on January 31, 2023 representing 20,000 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2024.
- [F5]The reporting person was granted RSUs on January 31, 2024 representing 16,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2025.
- [F6]1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2026, January 31, 2027 and January 31, 2028.